Listing of Claims

1-60. Canceled

61. (Previously Presented) A composition comprising an anticoagulant agent and a protein C or activated protein C polypeptide comprising a modified GLA domain, said modified GLA domain comprising the amino acid sequence of SEQ ID NO:1 with one, two, three, four, or five amino acid substitutions at positions selected from the group consisting of residues 10, 11, 28, 32, and 33.

62. (Previously Presented) The composition of claim 61, wherein said anticoagulant agent is aspirin, warfarin, or heparin.

63. (Previously Presented) The composition of claim 61, wherein said anticoagulant agent is aspirin.

64. (Previously Presented) The composition of claim 61, wherein said one amino acid substitution is at residue 10.

65. (Previously Presented) The composition of claim 61, wherein said one amino acid substitution is at residue 11.

66. (Previously Presented) The composition of claim 61, wherein said one amino acid substitution is at residue 28.

67. (Previously Presented) The composition of claim 61, wherein said one amino acid substitution is at residue 33.

68. (Previously Presented) The composition of claim 61, wherein said modified GLA domain comprises the amino acid sequence of SEQ ID NO:1 with three amino acid substitutions at residues 11, 32, and 33.

69. (Previously Presented) The composition of claim 68, wherein residue 32 of SEQ ID NO:1 is glutamic acid and residue 33 of SEQ ID NO:1 is aspartic acid.

70. (Previously Presented) The composition of claim 69, wherein residue 11 of SEQ ID NO:1 is glycine.

71. (New) The composition of claim 61, wherein said modified GLA domain comprises the amino acid sequence of SEQ ID NO:1 with two amino acid substitutions at residues 32 and 33.

72. (New) The composition of claim 71, wherein residue 32 of SEQ ID NO:1 is glutamic acid and residue 33 of SEQ ID NO:1 is aspartic acid.